In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...

Demand for the drugmaker’s Paxlovid treatment spurred by the latest COVID wave and a US national stockpile delivery led to US$2.7 billion in sales for the drug, Pfizer said Tuesday (Oct 29).

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) approved PAXLOVID™ (nirmatrelvir tablets and ritonavir tablet ...

Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance Removes a Significant Uncertainty by Providing Pathway to U.S. Commercialization of Paxlovid on January ...

I remain bearish on Pfizer due to pricing pressures from IRA/340B and a looming 2026 patent cliff, despite Q2 2025 earnings beat.

June 7 (Reuters) - A 15-day course of Pfizer's (PFE.N) COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers.

Pfizer will price a five-day course of its Covid antiviral drug Paxlovid at $1,390 when the company starts to transition it to the commercial market later this year.

Pfizer’s Paxlovid is linked to far higher rate of COVID rebound: study Nov. 14, 2023 7:34 AM ET Pfizer Inc. (PFE) Stock By: Dulan Lokuwithana, SA News Editor 109 Comments ...

Pfizer said Paxlovid, which consists of two different antiviral drugs, is currently approved or authorized for conditional or emergency use in more than 60 countries across the globe to treat high ...

Paxlovid, which combines a new Pfizer pill with the old antiviral ritonavir, is currently authorized for use in the first days of a COVID infection to prevent severe disease in high-risk patients.

Paxlovid, which Pfizer expects to earn it $22 billion this year, is a combination of two antiviral drugs called nirmatrelvir and ritonavir. Recent trials have shown that for high-risk patients ...